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Background: In pregnancies complicated by early-onset extreme fetal growth restriction, there is a high risk of
preterm birth and an overall dismal fetal prognosis. Sildenafil has been suggested to improve this prognosis.
The first aim of this review is to assess whether sildenafil benefits or harms these babies. The second aim is to
analyse if these effects are modified in a clinically meaningful way by factors related to the women or the trial
protocol.
Methods/Design: The STRIDER (Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction)
Individual Participant Data (IPD) Study Group will conduct a prospective IPD and aggregate data systematic review with
meta-analysis and trial sequential analysis. The STRIDER IPD Study Group started trial planning and funding applications
in 2012. Three trials will be launched in 2014, recruiting for three years. Further trials are planned to commence in 2015.
The primary outcome for babies is being alive at term gestation without evidence of serious adverse neonatal
outcome. The latter is defined as severe central nervous system injury (severe intraventricular haemorrhage (grade 3
and 4) or cystic periventricular leukomalacia, demonstrated by ultrasound and/or magnetic resonance imaging) or
other severe morbidity (bronchopulmonary dysplasia, retinopathy of prematurity requiring treatment, or necrotising
enterocolitis requiring surgery). The secondary outcomes are improved fetal growth velocity assessed by ultrasound
abdominal circumference measurements, gestational age and birth weight (centile) at delivery, and age-adequate
performance on the two-year Bayley scales of infant and toddler development-III (composite cognitive score
and composite motor score). Subgroup and sensitivity analyses in the IPD meta-analysis include assessment of
the influence of several patient characteristics: an abnormal or normal serum level of placental growth factor,
absent/reversed umbilical arterial end diastolic flow at commencement of treatment, and other patient characteristics
available at baseline such as gestational age and estimated fetal weight. The secondary outcomes for mothers include
co-incidence and severity of the maternal syndrome of pre-eclampsia, mortality, and other serious adverse events.
Discussion: Trials are expected to start in 2013–2014 and end in 2016–2017. Data analyses of individual trials are
expected to finish in 2019. Given the pre-planned and agreed IPD protocol, these results should be available in 2020.
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Severe early-onset fetal growth restriction (FGR) compli-
cates approximately 0.4% of pregnancies and severely in-
creases the risk of perinatal morbidity and mortality. This
is particularly due to premature delivery, both for fetal
and for secondary maternal indications such as the devel-
opment of pre-eclampsia [1]. Placental disease, conse-
quent on deficient uteroplacental blood flow, includes
FGR, pre-eclampsia, and placental abruption and has been
implicated in more than 50% of iatrogenic premature
births [2]. For this reason, the problem of severe FGR
forms a substantial portion of the population that tertiary
care centres care for.
The effect of severe early-onset FGR is particularly sig-
nificant: of those born alive, less than a third will survive
their neonatal intensive care unit (NICU) stay without
significant neurodevelopmental sequelae. Survival rates
for severely growth-restricted fetuses very remote from
term (<28 weeks’ gestation) vary from 7% to 33% [1,3,4].
As these early-onset FGR children are born very pre-
term, there are significant risks of neonatal mortality,
major and minor morbidity, and long-term health seque-
lae [5,6]. These are not only strongly gestational-age re-
lated [7], but are also related to FGR [8]. Although most
of the surviving children are without severe disabilities
at school age, many of them meet serious difficulties in
everyday life and the burden of mild developmental ab-
normalities and behavioural and learning disorders in-
creases with age. In adolescents, as many as 40% of the
survivors will not be able to become fully independent
adults [9].
The direct costs of care include the increased cost of
intensive antenatal surveillance (with or without a period
of hospitalisation), caesarean delivery (if considered vi-
able), NICU care, routine post-NICU follow-up, need for
special schooling and educational support (speech ther-
apy, physical therapy, psychological support), and, often,
specialised neurodevelopmental assessments and inter-
ventions. Such costs are in addition to the indirect costs
to families (grief, lost wages, supportive services, and re-
lationship stress) and represent a considerable economic
burden. Safe pregnancy prolongation accompanied by
additional fetal growth would be associated with signifi-
cant societal and financial savings.
The use of ultrasound Doppler waveform analysis in
pregnancies complicated by FGR suggests compromised
uteroplacental circulation and placental hypoperfusion.
Currently there are no specific evidence-based therapies
for placental insufficiency and early-onset severe FGR.
Non-specific interventions include primarily lifestyle mod-
ifications, such as reducing or stopping work, stopping
aerobic exercise, rest at home, and hospital admission for
rest and surveillance. These interventions, which are not
supported by evidence from randomised trials, are used inthe belief that rest will enhance the uteroplacental circula-
tion at the expense of that to the glutei and quadriceps
muscles.
There is evidence from ex vivo and animal models of
growth restriction that the phosphodiesterase 5 inhibitor
sildenafil citrate increases average pup birth weight and
improves uteroplacental blood flow (umbilical artery,
uterine artery) [10-12]. Sildenafil citrate may thus offer a
potential therapeutic strategy to improve uteroplacental
blood flow in human pregnancies complicated by severe
FGR [12]. There is evidence, albeit limited, to support
the use of sildenafil in human pregnancy. A small trial in
women with early-onset pre-eclampsia (a maternal pres-
entation of placental compromise) showed no resolution
of pre-eclampsia, but an effect on birth weight [13]. In
addition, a small cohort study showed a tendency to-
wards more live-born children that survived intact to pri-
mary discharge after sildenafil intervention [14]. From all
observations thus far, there are no indications that sildena-
fil in the second trimester has significant fetotoxicity.
Coordinated initiatives have been launched and ap-
proved/shortlisted for funding in networks in the United
Kingdom/Ireland, The Netherlands, and New Zealand/
Australia. Initiatives in Canada and the United States of
America are in an earlier phase. These trials are embed-
ded in a global network (Global Obstetrics Network –
GONet) [15]. This network was initiated to provide a
forum for international interaction and foster communi-
cation between groups that perform clinical studies in
obstetrics. GONet has started the collaborative initiative
to resolve the underlying question: does sildenafil versus
placebo improve outcomes in early-onset severely growth
restricted fetuses with a dismal prognosis? Within each
part of the network, stand-alone randomised clinical trials
will be conducted; a prospective systematic review with
meta-analyses and trial sequential analyses of individual
participant data (IPD) and aggregate data will then be per-
formed. The concerted effort in the design and conduct of
these large international studies provides an efficient use
of scarce resources and will optimise resolution of the re-
search questions, in addition to facilitating adequate
power for subgroup analyses.
Methods/Design
Study design
Prospectively planned systematic review with IPD and
aggregate data meta-analysis [16] and trial sequential
analysis [17-21] of randomised clinical trials comparing
sildenafil with matching placebo tablets or no interven-
tion for treatment of severe early-onset FGR.
Inclusion and exclusion criteria for the studies
Studies, published or unpublished, will be included if
they are randomised clinical trials. Other study designs
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assessment of harm we will also include observational
studies. Given the pre-planned nature of the IPD meta-
analysis, most or all studies will have been identified be-
fore the start of the individual trials and will participate
in central data collection. If other trials, yet unknown,
are conducted simultaneously, their eligibility will be
assessed independently and unblinded for author and
journal by two members of the Sildenafil Therapy In
Dismal prognosis Early-onset intrauterine growth Re-
striction (STRIDER) IPD Study Group. Any differences
in opinion regarding eligibility will be resolved by dis-
cussion. If the study design is suboptimal for IPD meta-
analysis or the authors do not cooperate, the study will
be included for aggregate data analysis.
We will use the Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE, Embase, LILACS,
and Science Citation Index Expanded using the terms
“fetal growth retardation” and “sildenafil”. In addition,
we will access the WHO Trial Portal [22], Current Con-
trolled Trials [23], the Australian and New Zealand Trials
Register [24], and the ISRCTN register [25] to identify re-
cently completed or ongoing trials. Experts in the field
and trialists will be asked if they know of any unpublished
or other trials. The currently known trials that will be con-
ducted and included are:
UK/Ireland: Planned sample size 112; primary
outcome: prolongation of gestational age at birth.
The Netherlands: Planned sample size 354; primary
outcome: infant survival to term age without evidence
of serious adverse neonatal outcome.
New Zealand/Australia: Planned sample size 122;
primary outcome: fetal growth velocity.
Canada: Planned sample size 90; primary outcome:
fetal growth velocity.
Types of participants
Women with a singleton pregnancy between 20 + 0 and
29 + 6 weeks with severe fetal growth restriction of likely
placental origin, and with estimated significant likeli-
hood of fetal/neonatal death.
Type of intervention
Sildenafil versus placebo tablet orally or versus no inter-
vention until fetal death, delivery, or 32 weeks of gesta-
tion (whichever comes first). Co-interventions will be
allowed provided they are administered similarly in the
intervention groups.
Data collection and management
The investigators of each individual trial have designed
each trial together before launch and patient recruit-
ment. All of the listed eligible trials that have agreed tojoin the STRIDER Study Group have agreed a common
core data set and have agreed to supply their trial’s IPD
to a central repository. Randomisation will be centrally
controlled using an on-line computerised randomisation
service. All have agreed to collect all relevant variables
on baseline characteristics and outcomes (the primary
and secondary outcomes of this protocol). All have
agreed to centrally collect data. The University of British
Columbia (UBC) will host data management through
the UBC Perinatal Clinical Trials Unit. Wherever pos-
sible, data will be collected as continuous rather than
dichotomous measurements. All trialists have agreed
to collect information on the number of eligible but
not-included patients. If the patient consents, a number
of relevant baseline and outcome parameters will be
collected.
If other relevant randomised clinical trials are identi-
fied, data collected from those studies will include all
women randomised and coded for anonymity (date of
birth, centre identification), baseline data for descriptive
purposes and analyses, details of the intervention given
(date of randomisation, allocated intervention), and out-
comes, to allow planned analyses. Trialists will provide
non-identified IPD in any convenient format by encrypted,
electronic transfer where possible or other means as
needed. The individual trial data will be recoded as re-
quired, and stored in the secure database that will only be
accessible by authorised personnel of the UBC Perinatal
Clinical Trials Unit. Trialists will be asked to verify all
recoded data prior to any analysis and the data will not be
used for any other purpose without permission of all
collaborators.
The data will be checked with respect to range, in-
ternal consistency, missing or extreme values, errors,
and consistency with published reports. Trial details,
such as randomisation methods, blinding, and interven-
tion details, will be crosschecked against published reports,
trial protocols, and data collection sheets. Inconsistencies
or missing data will be discussed with the individual trial-
ists and attempts will be made to resolve any problems by
consensus.
Data items to be collected
Trial level information
1. Dates the trial opened and closed accrual.
2. Number of participants randomised.
3. Informed consent procedures.
4. Methods of random allocation.
5. Stratification factors (if any).
6. Methods of allocation concealment.
7. Blinding procedures for outcome assessment.
8. Details of the planned intervention in the drug arm:
frequency, timing, doses.
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arm: frequency, timing, doses.
Participant-level information – maternal characteristics at
study entry
1. Unique identification coded for anonymity.
2. Maternal age.
3. Body mass index.
4. Parity.
5. Abdominal circumference.
6. Ethnicity.
7. Hypertensive disease (type of ).
8. Uterine artery notching/pulsatility index.
9. Placental growth factor levels in maternal serum.
10.Treatment (e.g., aspirin, low molecular weight
heparin, oral steroids, insulin).
Participant-level information – fetal characteristics at study entry
1. Estimated due date.
2. Date and time of randomisation.
3. Estimated fetal weight, abdominal circumference.
4. Absent or reversed end-diastolic flow of the umbil-
ical artery, pulsatility index.
5. Pulsatility index of middle cerebral artery.
Participant-level information – maternal information after
trial entry
1. Date and time of prenatal corticosteroid treatment.
2. Hypertensive disease (type of ).
3. Highest blood pressure measured.
4. Proteinuria (maximum level recorded).
5. Platelet count (lowest recorded).
6. Adverse events and adverse effects for the woman at
time of treatment and post-partum.
Participant-level information – fetal information after trial entry
1. Sequential assessments of the umbilical artery: absent
or reversed end-diastolic flow, pulsatility index.
2. Sequential assessments of estimated fetal weight,
abdominal circumference.
3. Sequential assessments of the middle cerebral artery:
pulsatility index.
4. Estimated date and time if fetal death.
5. Adverse events and adverse effects for the fetus.
Participant-level information – neonatal information after
trial entry
1. Unique baby information and mother identification
coded for anonymity.2. Date and time of delivery.
3. Birth weight, 5 minute Apgar scores, sex.
4. Mode of delivery.
5. Neonatal morbidity.
6. Date and time if neonatal death.
7. Childhood follow-up assessment.
8. Adverse events and adverse effects for the neonate.
Participant-level information – data on actual trial intervention
1. Type of treatment given (placebo, sildenafil, dose).
2. Number of doses actually given.
3. Interval between first dose and 32 weeks or delivery
or fetal death.
4. Total actual drug exposure.
Bias risk assessments
This project will use the Cochrane Collaboration methods
for assessing risk of bias within individual trials [26]:
Allocation sequence generation
Low risk of bias: sequence generation was achieved
using computer random number generation or a
random number table. Drawing lots, tossing a coin,
shuffling cards, and throwing dice are adequate if
performed by an independent person not otherwise
involved in the trial.
Uncertain risk of bias: the method of sequence
generation was not specified.
High risk of bias: the sequence generation method
was not random.
Allocation concealment
Low risk of bias: the participant allocations could not
have been foreseen in advance of, or during, enrolment.
Allocation was controlled by a central and independent
randomisation unit. The allocation sequence was
unknown to the investigators (for example, if the
allocation sequence was hidden in sequentially
numbered, opaque, and sealed envelopes).
Uncertain risk of bias: the method used to conceal the
allocation was not described so that intervention
allocations may have been foreseen in advance of, or
during, enrolment.
High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants, personnel, and outcome assessors
Low risk of bias: blinding was performed adequately or
the assessment of outcomes was not likely to be
influenced by lack of blinding.
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information to assess whether blinding was likely to
induce bias on the results.
High risk of bias: no blinding or incomplete blinding,
and the assessment of outcomes were likely to be
influenced by lack of blinding.
Incomplete outcome data
Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values.
Sufficient methods, such as multiple imputation, have
been employed to handle missing data.
Uncertain risk of bias: there was insufficient
information to assess whether missing data in
combination with the method used to handle missing
data were likely to induce bias on the results.
High risk of bias: the results were likely to be biased
due to missing data.
Selective outcome reporting
Low risk of bias: all outcomes were pre-defined and re-
ported or all clinically relevant and reasonably expected
outcomes were reported.
Uncertain risk of bias: it was unclear whether all pre-
defined and clinically relevant and reasonably ex-
pected outcomes were reported.
High risk of bias: one or more clinically relevant and
reasonably expected outcomes were not reported, and
data on these outcomes were likely to have been
recorded.
For a trial to be assessed with low risk of bias in the
selective outcome reporting domain, the trial should
have been registered either on the www.clinicaltrials.
gov website or a similar register, or there should be a
protocol, e.g., published in a paper journal. In the case
when the trial was run and published in the years
when trial registration was not required, we carefully
scrutinised all publications reporting on the trial to
identify the trial objectives and outcomes. If usable
data on all outcomes specified in the trial objectives
were provided in the publications results section, then
the trial was considered low risk of bias trial in the
Selective outcome reporting domain.
Industry bias
Low risk of bias: the trial appears to be free of industry
sponsorship that may manipulate the trial design,
conductance, or results of the trial.
Uncertain risk of bias: the trial may or may not be
free of for-profit bias as no information on clinical
trial support or sponsorship is provided.High risk of bias: the trial is sponsored by the
industry.
Other bias
Low risk of bias: the trial appears to be free of other
components that could put it at risk of bias.
Uncertain risk of bias: the trial may or may not be
free of other components that could put it at risk of
bias.
High risk of bias: there are other factors in the trial
that could put it at risk of bias.
Trials assessed as having ‘low risk of bias’ in all of the
individual domains specified in the review were
considered ‘trials with low risk of bias’. Trials assessed
as having ‘uncertain risk of bias’ or ‘high risk of bias’
in one or more of the specified in the review
individual domains were considered trials with ‘high
risk of bias’ [26-30].
Dealing with missing data
We intend to perform an intention-to-treat analysis when-
ever possible. We will impute data for binary outcomes
using various scenarios, namely best-best analysis, worst-
worst analysis, best-worst analysis, and worst-best analysis.
For continuous outcomes, we will use available-participant
analysis. We will impute the standard deviation from P
values according to the instructions given in the Cochrane
Handbook for Systematic Reviews of Intervention [26] and
use the median for the meta-analysis when the mean is not
available. If it is not possible to calculate the standard devi-
ation from the P value or the confidence intervals (CIs), we
will impute the standard deviation as the highest standard
deviation in the other trials included under that outcome,
fully recognising that this form of imputation will decrease
the weight of the trial for calculation of mean differences
and bias the effect estimate to no effect in the case of stan-
dardised mean difference.
Outcomes
The primary outcome is defined as:
Neonatal survival until term age without serious neo-
natal morbidity defined as secondary outcomes 3–6. The
outcome needs to be assessed formally at term age by
clinic visit (or as a last-resort alternative by telephone).
Secondary outcomes are:
1. Any perinatal deaths (any know death irrespective of
cause).
2. Perinatal deaths in normally formed infants (absence
of severe congenital malformation, infection, or
genetic abnormality).
3. Severe central nervous system injury (diagnosed by
ultrasound and/or magnetic resonance imaging)
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intracerebral haemorrhage grade III or more, or
hydrocephalus.
4. Bronchopulmonary dysplasia (the requirement of
ambulatory oxygen therapy >36 weeks corrected
gestational age).
5. Retinopathy of prematurity (requiring treatment
such as laser therapy; grade 2/3 or more).
6. Necrotising enterocolitis (requiring surgery).
7. Need for inotropes or vasopressors: number of days
on inotropes or vasopressors, days on one, two, or
three different inotropes or vasopressors.
8. Patent ductus arteriosus needing medical or surgical
treatment.
9. Number of septic episodes, defined as culture
proven or clinical, with need for antibiotics for 5 or
more days.
10. Total number of days on artificial ventilation.
11. Postmenstrual age at discharge home.
12. Corrected age-adequate performance (both compos-
ite cognitive score [Mental Developmental Index]
and composite motor score [Psychomotor Develop-
mental Index] continuously and <85) on the two-
year Bayley scales of infant and toddler
development-III; cerebral palsy rate including sever-
ity scaling with Gross Motor Function Classification
Scale and a Child Behaviour Check List
-questionnaire.
13. Fetal growth velocity, measured by expected/
observed average daily increase in ultrasound-
estimated
abdominal circumference.
14. Birth weight (grams, centiles).
15. Gestational age at delivery (days).
16. Co-incidence and severity of the maternal syndrome
of pre-eclampsia/hemolysis, elevated liver enzymes,
low platelets syndrome.
17. Maternal hypertension requiring treatment.
Safety monitoring (mother)
18. Serious adverse events.
19. Suspected unexpected serious adverse reaction.
20. Anything else considered an adverse event.
Safety monitoring (fetus)
21. Serious adverse events.
22. Suspected unexpected serious adverse reaction.
23. Anything else considered an adverse event.
Statistical analyses
The detailed statistical analysis plan will be prepared and
agreed upon by the STRIDER IPD Study Group prior tothe data analyses. Any analyses conducted will be based
on the checked and updated individual participant data
from all available trials. All randomised participants with
outcome data available will be included in the analyses,
which will be performed on an intention-to-treat basis,
according to the treatment allocation at randomisation.
For each of the outcomes (as well as the individual
components of each composite outcome), a one-stage
approach to analysis will be taken so that the IPD from
all eligible trials are included in a single model. Fitting a
single model for each outcome variable will enable the
variation across trials to be accounted for within the
model by including a fixed trial effect. A treatment by
trial interaction term will be tested to assess heterogeneity
of treatment effect across trials. If excessive statistical het-
erogeneity in treatment effect or inconsistency across tri-
als is detected (that is, if the trial by treatment interaction
term is significant), then the rationale for combining
trials will be questioned and the source of heterogen-
eity explored.
Binary outcomes will be analysed using log binomial
regression models and results will be presented as risk
ratios with 95% CI and associated two-sided P values.
Continuous outcomes will be analysed using linear re-
gression models and results will be presented as differ-
ences in means with 95% CI and two-sided P values.
Any differences in treatment effect between pre-specified
subgroups of clinical characteristics at inclusion or at any
time (gestational age, absent-reversed end-diastolic flow in
the umbilical artery, placental growth factor maternal
serum levels, maternal disease present or absent) will be
assessed by testing a treatment by subgroup interaction
term within the model.
Trial sequential analysis
Trial sequential analysis will be applied to the meta-
analyses combining IPD and aggregate data because cu-
mulative meta-analyses are at risk of producing random
errors due to sparse data and repetitive testing of the ac-
cumulating data [16-21]. The underlying assumption of
trial sequential analysis is that testing for significance
may be performed each time a new trial is added to the
meta-analysis resulting in an increased risk of random
errors. We will add the trials according to the year of
publication, and if more than one trial is published in a
year, the trials will be added alphabetically according to
the last name of the first author. On the basis of the
diversity-adjusted required information size, trial sequen-
tial monitoring boundaries will be constructed. These
boundaries determine the statistical inference one may
draw regarding the cumulative meta-analysis that has not
reached the required information size; if the trial sequen-
tial monitoring boundary is crossed before the required
information size is reached, firm evidence may perhaps be
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ous. On the other hand, if the boundary is not surpassed,
it will most probably be necessary to continue conducting
trials in order to detect or reject a certain intervention
effect.
We will apply trial sequential analysis using a diversity-
adjusted required information size calculated from an
alpha error of 0.05, a beta error of 0.20, the control event
proportion obtained from the results of the meta-analysis,
and a relative risk reduction of 20% for binary outcomes
with two or more trials to determine whether more trials
are necessary on this topic (if the trial sequential alpha-
spending monitoring boundary or the futility zone is
crossed, then more trials may be unnecessary). For
continuous outcomes, the required sample size will be
calculated from an alpha error of 0.05, a beta error of
0.20, the variance estimated from the meta-analysis re-
sults, and a minimal clinically relevant difference will
be defined for each of the continuous outcomes.
Planned subgroup analyses
We plan the following subgroup analyses:
 IPD trials compared to trials only providing
aggregate data.
 Trials with low risk of bias compared to trials with
high risk of bias.
 Trials with dose of intervention below the median
compared to trials with dose of intervention above
the median.
Planned sensitivity analyses
To assess whether the results are robust to trial design
and quality, sensitivity analyses will be performed on the
primary outcome to test changes of the results after ex-
clusion of trials with smaller sample size, centres with
smaller sample size, and trials/centres with high rate of
missing values. We will impute data for binary missing
outcomes using various scenarios, namely best-best ana-
lysis, worst-worst analysis, best-worst analysis, and worst-
best analysis.
Multiple comparisons
A very large number of outcomes are being investigated
in this study, which increases the risk of observing ‘false
positive’ results due to multiplicity. However, all out-
comes are important in giving a full clinical picture that
considers the benefits and risks to both mothers and in-
fants. We do not plan formal statistical adjustment of P
values to account for multiple comparisons due to the
non-independence of outcomes in this study. Results
will be interpreted with caution. Decisions as to whether
the intervention should be recommended will be basedprimarily on the primary outcome of the fetus and will
consider any adverse effects on the mother and/or child.
Ethics and management issues
Participants in the individual trials have given informed
consent to participate in their respective trial. The data
for this project are to be used for the purpose for which
they were originally collected and are available through
an agreement between all trialists of the collaborative
group. These trialists remain the custodians of their ori-
ginal individual trial data at all times.
Project management
For the purpose of this project, the international
STRIDER IPD Study Group will manage the project.
Additionally, the coordinating investigator of each trial
will be invited to become a member of the STRIDER
IPD Study Group. The Study Group and statisticians
from the data management centre will develop the stat-
istical analysis plan. The data management centre will be
responsible for the storage and analyses of the IPD pro-
ject data.
The Study Group meetings
Study Group face-to-face meetings will be organised at
least twice during the study. Representatives of all eli-
gible trials will be invited to attend those meetings. The
meetings will be scheduled, if possible, in conjunction
with international conferences. During those meetings,
various aspects of the project will be discussed with all
the collaborators, such as the project design and con-
duct, the analysis plan, and the interpretation and
reporting of the results.
The final results of the study will be presented to the
collaborators for discussion. The main manuscript will
be prepared by the STRIDER IPD Study Group. The re-
vised draft paper will be circulated for final comment
and agreement prior to publication. Publications arising
from these data will be authored by all members of the
STRIDER IPD Study Group on behalf of all other collab-
orators participating, who will be acknowledged within
the manuscript.
Discussion
Severe early-onset FGR due to placental insufficiency is
associated with a high risk of perinatal morbidity with
long-lasting sequelae and mortality. Placental insuffi-
ciency is the result of abnormal formation and function
of the placenta (placentation) with inadequate remodel-
ling of the maternal spiral (uteroplacental) arteries.
There is currently no therapy available with demon-
strated effectiveness, making monitoring and timely de-
livery of the child the only treatment option. Both
in vitro and in vivo evidence suggests sildenafil citrate as
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flow, fetal growth, and meaningful outcomes in FGR
pregnancies.
On the basis of preliminary research, some centres are
already adopting the treatment with sildenafil. There is,
however, significant uncertainty regarding the true health
benefits, if any. Moreover, potential harm is not yet ex-
cluded. Fetotoxicity has not been described yet, but is the-
oretically possible. For these reasons, evidence from
randomised clinical trials is needed before widespread im-
plementation [31].
Given the sample size issues, no single randomised
clinical trial will ultimately be likely to give the answers
to the questions posed in this study. For this reason,
simultaneous smaller and medium-sized randomised
clinical trials have been planned and funded. The present
pre-planned systematic review with IPD meta-analysis will
allow more definite answers, including effect modifica-
tions in relevant subgroups. Furthermore, the totality of
evidence from IPD trials and trials reporting only aggre-
gate data can be assessed and evaluated with GRADE
methodology [32]. All weighing of results should take into
consideration risks of bias and aim to minimise these: sys-
tematic errors (bias) due to methodology and design; risks
of academic bias if there are conflicting results between
studies from this GONet group and other studies; risks of
random errors (play of chance) [33]. According to our
knowledge, this is the first time a protocol for a systematic
review has been finalised and published before the first
larger trial has been launched on a topic. With the All-
Trials initiative and other initiatives for transparency in
clinical research, we hope that the number of trials provid-
ing IPD for this systematic review will be large.
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